A Case of Primary Amyloidosis Involving Liver, Stomach, Intestines, and Heart without Evident Kidney Involvement
https://doi.org/10.22416/1382-4376-2021-31-6-47-55
Abstract
Aim. Systemic amyloidosis caused by the synthesis and deposition of immunoglobulin light chains (AL amyloidosis) is a relatively rare disease that involves heart, kidneys, peripheral nervous system, gastrointestinal tract, and has a large number of various clinical manifestations. We present a clinical case of systemic AL amyloidosis with a predominant involvement of liver, stomach, intestines, and heart in a Caucasian female.
Key points. A Caucasian woman presented to clinic with severe general weakness, abdominal pain, diarrhea, sudden weight loss, and palpitation. Initial examination revealed a duodenal bulb ulcer complicated by bleeding and polyps in the retrobulbar part of duodenum. Decreased hemoglobin levels, elevated levels of alkaline phosphatase, gamma-glutamyltransferase, and N-terminal prohormone of brain natriuretic peptide, signs of heart failure with preserved ejection fraction, and hepatomegaly became the basis for a clinical suspicion of AL amyloidosis and puncture liver biopsy. Histochemical and immunohistochemical studies of liver, stomach, and duodenum biopsy specimens confirmed AL amyloidosis. Timely diagnosis made it possible to conduct a specific therapy with melphalan plus dexamethasone, get a satisfactory response and improve the patient’s condition.
Conclusion. A thorough examination of patients along with a pathomorphological and immunohistochemical study of the biopsy specimens is the basis for confirming the diagnosis of AL amyloidosis, selecting the proper therapy, improving the condition of patients and their survival.
About the Authors
L. S. Kholopov
Odessa National Medical University
Ukraine
Ukraine
Leonid S. Kholopov — MD, PhD, Associate Professor, Department of Internal Medicine #2, Center of Reconstructive and Restorative Medicine (University Clinic),
Marshala Malynovskoho str., 67/14, Odessa, 65074
N. B. Gubegrits
Into-Sana Multifield Clinic
Ukraine
Ukraine
Natalya B. Gubegrits — Dr. Sci. (Med.), Prof., Gastroenterologist,
Varnenskaya str., 2, Odessa, 65000
O. A. Dyadyk
Shupyk National Healthcare University of Ukraine
Ukraine
Ukraine
Olena A. Dyadyk — Dr. Sci. (Med.), Prof., Head of Department of Pathological and Topographic Anatomy,
Dorogozhitska str., 9, Kiyv, 04112
Yu. E. Chirkov
Oberig Universal Clinic
Ukraine
Ukraine
Yuriy E. Chirkov — Cand. Sci. (Med.), Radiologist, Diagnostic Department,
Zoologichna str., 3, Kiyv, 03057
Yu. V. Tsohoyeva
Odessa National Medical University
Ukraine
Ukraine
Yuliya V. Tsohoyeva — MD, Cardiologist, Department of Internal Diseases, Center of Reconstructive and Restorative Medicine (University Clinic),
Marshala Malynovskoho str., 67/14, Odessa, 65074
References
1. Benson M.D., Buxbaum J.N., Eisenberg D.S., Merlini G., Saraiva M.J.M., Sekijima Y., et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217–22. DOI: 10.1080/13506129.2020.1835263
2. Nuvolone M., Palladini G., Merlini G. Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis. Amyloid and Related Disorders. Current Clinical Pathology. 2015:9–29. DOI: 10.1007/978-3-319-19294-9_2
3. Merlini G., Dispenzieri A., Sanchorawala V., Schönland S.O., Palladini G., Hawkins P.N., Gertz M.A. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38. DOI: 10.1038/s41572-018-0034-3
4. Ghahghaei A., Faridi N.J. Review: structure of amyloid fibril in diseases. J Biomedical Science and Engineering. 2009;2:345–58. DOI: 10.4236/jbise.2009.25050
5. Dahiya D.S., Kichloo A., Singh J., Albosta M., Wani F. Gastrointestinal amyloidosis: A focused review. World J Gastrointest Endosc. 2021;13(1):1–12. DOI: 10.4253/wjge.v13.i1.1
6. den Braber-Ymker M., Heijker S., Lammens M., Croockewit S., Nagtegaal I.D. Intestinal involvement in amyloidosis is a sequential process. Neurogastroenterol Motil. 2018;30(12):e13469. DOI: 10.1111/nmo.13469.
7. Al Hamed R., Bazarbachi A.H., Bazarbachi A., Malard F., Harousseau J.L., Mohty M. Comprehensive Review of AL amyloidosis: some practical recommendations. Blood Cancer J. 2021;11(5):97. DOI: 10.1038/s41408-021-00486-4.
8. Muchtar E., Dispenzieri A., Gertz M.A., Kumar S.K., Buadi F.K., Leung N., et al. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clin Proc. 2021;96(6):1546–77. DOI: 10.1016/j.mayocp.2021.03.012.
9. Gavriatopoulou M., Musto P., Caers J., Merlini G., Kastritis E., van de Donk N., et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32(9):1883–98. DOI: 10.1038/s41375-018-0209-7
10. Posadas Martinez M.L., Aguirre M.A., Belziti C., Brouet E., Auteri M.A., Forte A.L., et al. Guía de Práctica Clínica para el diagnóstico de la amiloidosis: Parte 1/3. Año 2020 [Clinical Practice Guidelines for diagnosis of amyloidosis: Part 1/3 Year 2020]. Rev Fac Cien Med Univ Nac Cordoba. 2021;78(1):74–82. Spanish. DOI: 10.31053/1853.0605.v78.n1.30824
11. Picken M.M. The Pathology of Amyloidosis in Classification: A Review. Acta Haematol. 2020;143(4):322–34. DOI: 10.1159/000506696.
12. Kittleson M.M., Maurer M.S., Ambardekar A.V., Bullock-Palmer R.P., Chang P.P., Eisen H.J., et al. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142(1):e7–e22. DOI: 10.1161/CIR.0000000000000792
13. Gillmore J.D., Wechalekar A., Bird J., Cavenagh J., Hawkins S., Kazmi M., et al. BCSH Committee. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol. 2015;168(2):207–18. DOI: 10.1111/bjh.13156
14. Fotiou D., Dimopoulos M.A., Kastritis E. Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. Hemasphere. 2020;4(4):e454. DOI: 10.1097/HS9.0000000000000454
15. Palladini G. Management of AL amyloidosis in 2020. Blood. 2020;136(23):2620–7. DOI: 10.1182/blood.2020006913
16. Pedro L., Pinho R., Marques N. Amyloidosis — A review. Trends Med. 2019;19:1–6. DOI: 10.15761/TiM.1000206
17. Rowe K., Pankow J., Nehme F., Salyers W. Gastrointestinal Amyloidosis: Review of the Literature. Cureus. 2017;9(5):e1228. DOI: 10.7759/cureus.1228
Supplementary files
|
1. Неозаглавлен | |
| Subject | ||
| Type | Other | |
Download
(B)
|
Indexing metadata ▾ | |
Review
For citations:
Kholopov L.S., Gubegrits N.B., Dyadyk O.A., Chirkov Yu.E., Tsohoyeva Yu.V. A Case of Primary Amyloidosis Involving Liver, Stomach, Intestines, and Heart without Evident Kidney Involvement. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(6):47-55. https://doi.org/10.22416/1382-4376-2021-31-6-47-55
Views:
737
Email this article 
